Works by Goldschmidt, Neta

Results: 58
    1
    2
    3

    Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience.

    Published in:
    Leukemia & Lymphoma, 2021, v. 62, n. 1, p. 118, doi. 10.1080/10428194.2020.1824069
    By:
    • Segman, Yafit;
    • Ribakovsky, Elena;
    • Avigdor, Abraham;
    • Goldhecht, Yair;
    • Vainstein, Vladimir;
    • Goldschmidt, Neta;
    • Harlev, Shimrit;
    • Horwitz, Netanel;
    • Gutwein, Odit;
    • Gurion, Ronit;
    • Itchaki, Gilad;
    • Abadi, Uri;
    • Nemets, Anatoly;
    • Sofer, Orit;
    • Zektser, Miri;
    • Tadmor, Tamar;
    • Dally, Nagib;
    • Filanovsky, Kalman;
    • Leiba, Merav;
    • Sarid, Nadav
    Publication type:
    Article
    4
    5
    6
    7
    8
    9
    10
    11

    Efficacy of front‐line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real‐World" study.

    Published in:
    American Journal of Hematology, 2023, v. 98, n. 2, p. E24, doi. 10.1002/ajh.26779
    By:
    • Levi, Shai;
    • Bronstein, Yotam;
    • Goldschmidt, Neta;
    • Morabito, Fortunato;
    • Ziv‐Baran, Tomer;
    • Del Poeta, Giovanni;
    • Bairey, Osnat;
    • Del Principe, Maria Ilaria;
    • Fineman, Riva;
    • Mauro, Francesca Romana;
    • Gutwein, Odit;
    • Reda, Gianluigi;
    • Ruchlemer, Rosa;
    • Sportoletti, Paolo;
    • Laurenti, Luca;
    • Shvidel, Lev;
    • Coscia, Marta;
    • Tadmor, Tamar;
    • Varettoni, Marzia;
    • Aviv, Ariel
    Publication type:
    Article
    12
    13
    14
    15

    Richter's transformation to diffuse large B-cell lymphoma: A retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study Group.

    Published in:
    American Journal of Hematology, 2014, v. 89, n. 11, p. E218, doi. 10.1002/ajh.23826
    By:
    • Tadmor, Tamar;
    • Shvidel, Lev;
    • Bairey, Osnat;
    • Goldschmidt, Neta;
    • Ruchlemer, Rosa;
    • Fineman, Riva;
    • Rahimi-Levene, Naomi;
    • Herishanu, Yair;
    • Yuklea, Mona;
    • Arad, Ariela;
    • Aviv, Ariel;
    • Polliack, Aaron
    Publication type:
    Article
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28

    Predictive value of the CLL‐IPI in CLL patients receiving chemo‐immunotherapy as first‐line treatment.

    Published in:
    European Journal of Haematology, 2018, v. 101, n. 5, p. 703, doi. 10.1111/ejh.13149
    By:
    • Gentile, Massimo;
    • Shanafelt, Tait D.;
    • Mauro, Francesca Romana;
    • Reda, Gianluigi;
    • Rossi, Davide;
    • Laurenti, Luca;
    • Del Principe, Maria Ilaria;
    • Cutrona, Giovanna;
    • Angeletti, Ilaria;
    • Coscia, Marta;
    • Herishanu, Yair;
    • Chiarenza, Annalisa;
    • Molica, Stefano;
    • Ciolli, Stefania;
    • Goldschmidt, Neta;
    • Angrilli, Francesco;
    • Giordano, Annamaria;
    • Rago, Angela;
    • Bairey, Osnat;
    • Tripepi, Giovanni
    Publication type:
    Article
    29

    Outcomes of second‐line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials.

    Published in:
    European Journal of Haematology, 2018, v. 101, n. 3, p. 399, doi. 10.1111/ejh.13129
    By:
    • Joffe, Erel;
    • Goldschmidt, Neta;
    • Bairey, Osnat;
    • Fineman, Riva;
    • Ruchlemer, Rosa;
    • Rahimi‐Levene, Naomi;
    • Shvidel, Lev;
    • Greenbaum, Uri;
    • Aviv, Ariel;
    • Tadmor, Tamar;
    • Braester, Andrea;
    • Arad, Ariela;
    • Polliack, Aaron;
    • Herishanu, Yair;
    • The Israeli CLL Study Group
    Publication type:
    Article
    30
    31
    32
    33
    34
    35

    Risk factors and outcomes of COVID‐19 in adult patients with hematological malignancies: A single‐center study showing lower than expected rates of hospitalization and mortality.

    Published in:
    European Journal of Haematology, 2023, v. 111, n. 1, p. 135, doi. 10.1111/ejh.13977
    By:
    • Aumann, Shlomzion;
    • Tsubary, Uria;
    • Nachmias, Boaz;
    • Ben Yehuda, Dina;
    • Lavie, David;
    • Goldschmidt, Neta;
    • Vainstein, Vladimir;
    • Libster, Diana;
    • Saban, Revital;
    • Shaulov, Adir;
    • Israel, Sarah;
    • Avni, Batia;
    • Grisariu, Sigal;
    • Bdolah‐Amram, Tali;
    • Gatt, Moshe;
    • Zimran, Eran
    Publication type:
    Article
    36
    37
    38
    39

    Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/ CT is beneficial: a prospective multicentre trial of 355 patients.

    Published in:
    British Journal of Haematology, 2017, v. 178, n. 5, p. 709, doi. 10.1111/bjh.14734
    By:
    • Dann, Eldad J.;
    • Bairey, Osnat;
    • Bar‐Shalom, Rachel;
    • Mashiach, Tanya;
    • Barzilai, Elinor;
    • Kornberg, Abraham;
    • Akria, Luiza;
    • Tadmor, Tamar;
    • Filanovsky, Kalman;
    • Abadi, Uri;
    • Kagna, Olga;
    • Ruchlemer, Rosa;
    • Abdah‐Bortnyak, Roxolyana;
    • Goldschmidt, Neta;
    • Epelbaum, Ron;
    • Horowitz, Netanel A.;
    • Lavie, David;
    • Ben‐Yehuda, Dina;
    • Shpilberg, Ofer;
    • Paltiel, Ora
    Publication type:
    Article
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50

    Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant.

    Published in:
    2010
    By:
    • Koren-Michowitz M;
    • le Coutre P;
    • Duyster J;
    • Scheid C;
    • Panayiotidis P;
    • Prejzner W;
    • Rowe JM;
    • Schwarz M;
    • Goldschmidt N;
    • Nagler A;
    • Koren-Michowitz, Maya;
    • le Coutre, Philipp;
    • Duyster, Justus;
    • Scheid, Christof;
    • Panayiotidis, Panayiotis;
    • Prejzner, Witold;
    • Rowe, Jacob M;
    • Schwarz, Michaela;
    • Goldschmidt, Neta;
    • Nagler, Arnon
    Publication type:
    journal article